Current progress in the management of rare diseases and orphan drugs in China

Intractable and Rare Diseases Research

Volumn 1, Issue 2, 2012, Pages 45-52

  Gong, Shiwei ^a   Jin, Si ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

accessibility; management strategies; orphan drugs; Rare diseases

Indexed keywords

EID: 84945919084     PISSN: 21863644     EISSN: 2186361x     Source Type: Journal    
DOI: 10.5582/irdr.2012.v1.2.45     Document Type: Article

References (31)

1. Wang JB, Guo JJ, Yang L, Zhang YD, Sun ZQ, Zhang YJ. Rare diseases and legislation in China. Lancet. 2010; 375:708-709.
2. Hecht R, Wilson P, Palriwala A. Improving health r&d financing for developing countries: A menu of innovative policy options. Health Aff (Millwood). 2009; 28:974-985.
3. Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ. 2001; 79:735-741.
4. Villa S, Compagni A, Reich MR. Orphan drug legislation: Lessons for neglected tropical diseases. Int J Health Plann Manage. 2009; 24:27-42.
5. State Food and Drug Administration of China. Provisions for Drug Registration. http://eng.sfda.gov.cn/WS03/CL0768/61645.html(accessed April 22, 2012).
6. State Food and Drug Administration of China. Annual report of drug registration approval in 2010. http://www.sfda.gov.cn/WS01/CL0050/65856.html(accessed April 22, 2012).
7. State Food and Drug Administration of China. Requirements on Special Approval of New Drug Registration. http://www.sfda.gov.cn/WS01/CL0058/35157.html(accessed April 22, 2012).
8. State Food and Drug Administration of China. Provisions for in-Vitro Diagnostic Reagents Registration. http://www.sfda.gov.cn/WS01/CL0059/9418.html(accessed April 25, 2012).
9. Office of the State Council of the People's Republic of China. http://www.gov.cn/zwgk/2012-02/13/content_2065197.htm(accessed February 13, 2012).
10. State Food and Drug Administration of China. http://www.sfda.gov.cn/WS01/CL0784/25226.html(accessed April 25, 2012).
11. State Food and Drug Administration of China. http://www.sfda.gov.cn/WS01/CL0844/35759.html(accessed April 25, 2012).
12. Health News. http://www.jkb.com.cn/document.jsp?docid=288782(accessed April 18, 2012).
13. Ministry of Health of China. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3590/201104/51328.htm(accessed April 18, 2011).
14. Health News. http://www.jkb.com.cn/document.jsp?docid=289474&cat=0J(accessed April 18, 2012).
15. Haffner ME. The current environment in orphan drug development. Drug Information Journal. 2003; 37:373-379.
16. Dong K. Medical insurance system evolution in China. China Economic Review. 2009; 20:591-597.
17. Ministry of Health of China. Analysis report of National Health Services Survey in China, 2008. http://www.moh.gov.cn/sofpro/cms/previewjspfile/mohwsbwstjxxzx/cms CategoryID=8560(accessed April 28, 2012).
18. Guangzhou Daily. http://gzdaily.dayoo.com/html/2012-01/03/content_1577807.htm(accessed January 3, 2012).
19. West Business Daily. http://gov.gscn.com.cn/system/2012/04/09/010035856.shtml(accessed April 9, 2012).
20. Anhui News. http://ah.anhuinews.com/system/2011/12/12/004629271.shtml.(accessed April 10, 2012).
21. Ministry of Health of China. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohbgt/s3582/201202/54209.htm(accessed February 27, 2012).
22. Zhu F. Why should promote the reform of the public medical insurance program? Economy. 2011; 5:54-55. (in Chinese)
23. Gong SW, Zhang L, Jin S, Li LL. Management strategy for raising the accessibility to orphan drugs in China. Chinese Journal of Hospital Administration. 2010; 26:126-130. (in Chinese)
24. Qingdao Little Sunflower Hemophilia Foundation. http://society.people.com.cn/GB/41260/14790541.html(accessed January 20, 2012).
25. EURORDIS, About Orphan Drugs. http://www.eurordis.org/about-orphan-drugs (accessed February 20, 2012).
26. Ministry of Health of China. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/201105/51877.htm(accessed March 30, 2012).
27. Armstrong W. R&D-Pharma's Orphans-The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it? Pharmaceutical Executive, 2010:83.
28. Ten years of orphan medicines legislation in Europe-European Medicines Agency reviews success and looks ahead. http://www.ema.europa.eu/pdfs/general/direct/pr/29156010en.pdf (accessed March 28, 2012).
29. Cheng LG, Zhang Y. The New Rural Cooperative Medical Scheme: Financial protection or health improvement? Economic Research Journal. 2012; 1:120-133. (in Chinese)
30. People's Daily. http://www.rmlt.com.cn/News/201205/201205031850313501.html (accessed May 3, 2012).
31. Gong SW, Zhang L. Analysis of the demand characteristics of inpatients' medical care of common diseases and rare diseases in China. Chinese Health Economics. 2011; 30: 39-41. (in Chinese)